Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN

Current Biology

Volumn 11, Issue 10, 2001, Pages 764-768

  Patel, Lisa ^a   Pass, Ian ^b   Coxon, Phil ^a   Downes, C Peter ^b   Smith, Stephen A ^a   Macphee, Colin H ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; CELL DIFFERENTIATION; CELL FUNCTION; CELL NUCLEUS RECEPTOR; ENZYME ACTIVITY; GENE DISRUPTION; GENE EXPRESSION; GENETIC REGULATION; LIGAND; MONOCYTE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE; ROSIGLITAZONE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0035873953     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(01)00225-1     Document Type: Article

References (22)

1. Di Cristofano A., Pandolfi P.P. The multiple roles of PTEN in tumor suppression. Cell. 100:2000;387-390.
2. Kersten S., Desvergne B., Wahli W. Roles of PPARs in health and disease. Nature. 405:2000;421-424.
3. Sarraf P., Mueller E., Jones D., King F.J., DeAngelo D.J., Partridge J.B.et al. Differentiation and reversal of malignant changes in colon cancer through PPARγ Nat Med. 4:1998;1046-1052.
4. Sarraf P., Mueller E., Smith W.M., Wright H.M., Kum J.B., Aaltonen L.A., de la Chapelle A., Spiegelman B.M., Eng C. Loss-of-function mutations in PPAR γ associated with human colon cancer. Mol Cell. 3:1999;799-804.
5. Elstner E., Muller C., Koshizuka K., Williamson E.A., Park D., Asou H., Shintaku P., Said J.W., Heber D., Koeffler H.P. Ligands for peroxisome proliferator-activated receptorγ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 95:1998;8806-8811.
6. Maehama T., Dixon J.E. Pten. a tumour suppressor that functions as a phospholipid phosphatase Trends Cell Biol. 9:1999;125-128.
7. Jiang C., Ting A.T., Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature. 391:1998;82-86.
8. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 391:1998;79-82.
9. Marx N., Sukhova G., Murphy C., Libby P., Plutzky J. Macrophages in human atheroma contain PPARγ differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro Am J Pathol. 153:1998;17-23.
10. Huang J.T., Welch J.S., Ricote M., Binder C.J., Willson T.M., Kelly C., Witztum J.L., Funk C.D., Conrad D., Glass C.K. Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature. 400:1999;378-382.
11. Young P.W., Buckle D.R., Cantello B.C., Chapman H., Clapham J.C., Coyle P.J.et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ J Pharmacol Exp Ther. 284:1998;751-759.
12. Pesesse X., Moreau C., Drayer A.L., Woscholski R., Parker P., Erneux C. The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity. FEBS Lett. 437:1998;301-303.
13. Van der Kaay J., Beck M., Gray A., Downes C.P. Distinct phosphatidylinositol 3-kinase lipid products accumulate upon oxidative and osmotic stress and lead to different cellular responses. J Biol Chem. 274:1999;35963-35968.
14. Vanhaesebroeck B., Alessi D.R. The PI3K-PDK1 connection. more than just a road to PKB Biochem J. 3:2000;561-576.
15. Leevers S.J., Vanhaesebroeck B., Waterfield M.D. Signalling through phosphoinositide 3-kinases. the lipids take centre stage Curr Opin Cell Biol. 11:1999;219-225.
16. Torres J., Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 276:2001;993-998.
17. Di Cristofano A., Kotsi P., Peng Y.F., Cordon-Cardo C., Elkon K.B., Pandolfi P.P. Impaired Fas response and autoimmunity in Pten+/- mice. Science. 285:1999;2122-2125.
18. Egawa K., Sharma P.M., Nakashima N., Huang Y., Huver E., Boss G.R., Olefsky J.M. Membrane-targeted phosphatidylinositol 3-kinase mimics insulin actions and induces a state of cellular insulin resistance. J Biol Chem. 274:1999;14306-14314.
19. Fruman D.A., Mauvais-Jarvis F., Pollard D.A., Yballe C.M., Brazil D., Bronson R.T.et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 α Nat Genet. 26:2000;379-382.
20. Mueller E., Smith M., Sarraf P., Kroll T., Aiyer A., Kaufman D.S.et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci USA. 97:2000;10990-10995.
21. Demetri G.D., Fletcher C.D., Mueller E., Sarraf P., Naujoks R., Campbell N., Spiegelman B.M., Singer S. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA. 96:1999;3951-3956.
22. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 106:2000;523-531.